Natera, Inc. announced a new policy for national commercial coverage of its cell-free DNA (cfDNA) Fetal RhD noninvasive prenatal test (Fetal RhD NIPT). This coverage comes from one of the largest payors in the United States, effective January 2025.
The policy specifies that coverage for fetal RhD testing is available when a pregnancy may be at risk for alloimmunization, when paternal antigen typing is unavailable or heterozygous, and if a patient declines amniocentesis or it is not recommended. This expands access to important testing for RhD-negative pregnant patients, who constitute up to 15% of this population.
Broadening commercial coverage reinforces the clinical importance of this offering and its potential to prevent unnecessary medical treatment in pregnancies. This development is expected to drive increased adoption and utilization of Natera's Fetal RhD NIPT.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.